anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A three-arm protocol was performed. In protocol 1, participants ingested either a low-protein (LP) meal or a higher protein (HP) meal in a randomized order, separated by 72 h, followed by a 5-week low-protein, high-carbohydrate (LPHC) diet. In protocol 2 and 3, participants ingested either a LPHC diet or a low-protein, high-fat (LPHF) diet for 5 weeks followed by a higher protein diet (HPD) for another 5 weeks. All diets were eucaloric. Resting metabolic rate (RMR) was measured pre, during and post the protein-restricted interventions. A hyperinsulimic-euglycemic clamp was performed post the protein-restricted interventions and post the HPD interventions. A basal subcutaneous abdominal fat biopsy was obtained post the protein-restricted interventions and post the HPD interventions. In a run-in period over 14 days, the participant records the daily number of steps and physical activity, in order to determine their habitual activity level. During this period, a 4-day dietary record is performed, where all ingested food was weighed and recorded. During the experimental period the participant followed the supplied diet. All food consumed during the interventions was handed out to the subject at the institute. All food was packaged and weighed to 1 gram of accuracy. During the dietary intervention, a weekly test in the morning was performed, where the resting metabolic rate was measured and blood samples taken from the arm vein. At week 0, 5 and week 10 body composition was measured by dual energy x-ray absorptiometry scanning (DXA), and the fat biopsy was obtained . At all tests participants arrived fasting at the institute at 8:00 a.m. in the morning. The participant arrived by car or public transport.
The utility model discloses a solid preparation of a medicine for treating impotence and premature ejaculation, and provides a solid preparation of a medicine for selectively treating impotence and premature ejaculation. The pharmaceutical preparation comprises at least two structural units: (i) a structural unit, the material contains the medicinal component for treating impotence; (ii) also has a structural unit, and the material contains the medicinal component for treating premature ejaculation. The pharmaceutical preparation also comprises a linking unit, and the structural units are connected into a whole through the linking unit. Upon application of stress, the pharmaceutical formulation can break away from the linker unit, thereby permitting selective administration of the agents of either moiety alone or any combination of moieties. Different structural elements may be distinguished by having different colors or combinations of colors, having different shapes, being imprinted with different text, graphics or/and patterns, or combinations thereof. The utility model discloses a medicinal preparation design improves user's autonomic selectivity, and is more convenient, practical.
Methadone Hydrochloride Tablets may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of Methadone Hydrochloride Tablets and know how they will react to the medication [see Patient Counseling Information (17)].

###  5.18 Hypoglycemia

Cases of methadone-associated hypoglycemia have been reported, some resulting in hospitalization. In many cases, patients had predisposing risk factors (e.g., diabetes). The relationship between methadone and hypoglycemia is not fully understood but may be dose dependent. If hypoglycemia is suspected, monitor blood glucose levels, and manage the patient as clinically appropriate.
BACKGROUND: Molecular analysis of advanced tumors can increase tumor heterogeneity and selection bias. We developed a robust prognostic signature for gastric cancer by comparing RNA expression between very rare early gastric cancers invading only mucosal layer (mEGCs) with lymph node metastasis (Npos) and those without metastasis (Nneg).
METHODS: Out of 1003 mEGCs, all Npos were matched to Nneg using propensity scores. Machine learning approach comparing Npos and Nneg was used to develop prognostic signature. The function and robustness of prognostic signature was validated using cell lines and external datasets.
RESULTS: Extensive machine learning with cross-validation identified the prognostic classifier consisting of four overexpressed genes (HDAC5, NPM1, DTX3, and PPP3R1) and two downregulated genes (MED12 and TP53), and enabled us to develop the risk score predicting poor prognosis. Cell lines engineered to high-risk score showed increased invasion, migration, and resistance to 5-FU and Oxaliplatin but maintained sensitivity to an HDAC inhibitor. Mouse models after tail vein injection of cell lines with high-risk score revealed increased metastasis. In three external cohorts, our risk score was identified as the independent prognostic factor for overall and recurrence-free survival.
CONCLUSION: The risk score from the 6-gene classifier can successfully predict the prognosis of gastric cancer.
A low temperature, aqueous synthesis of polyhedral iron oxide nanoparticles (IONPs) is presented. The modification of the co-precipitation hydrolysis method with Triton X surfactants results in the formation of crystalline polyhedral particles. The particles are herein termed iron oxide “nanobricks” (IONBs), as the varieties of particles made are all variations on a simple “brick-like”, polyhedral shape such as rhombohedral shape or parallelogram as evaluated by TEM. These IONBs can be easily coated with hydrophilic silane ligands, allowing them to be dispersed in aqueous media. The dispersed particles are investigated for potential applications as hyperthermia and T 2  MRI contrast agents. The results demonstrate that the IONBs perform better than comparable spherical IONPs in both applications, and show r 2  values amongst the highest for iron oxide based materials reported in the literature.
The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
BACKGROUND: Chronic kidney disease is a progressive disease that affects more than 10% of the world's population and is also the leading cause of death in the twenty-first century. Furthermore, it imposes a significant financial burden on people undergoing hemodialysis. However, there is little research, particularly in the study area, on time to death and its predicators among hemodialysis patients in Ethiopia; therefore, knowing time to death and identifying predicators that affect survival time is crucial in order to improve survival time and enhance the prognosis of hemodialysis patients. The aim of this study was to assess time to death and its predictors among patients with chronic kidney disease on hemodialysis at a dialysis unit in Addis Ababa, Ethiopia, in 2023.
METHODS: An institution-based retrospective cohort study was carried out among 370 chronic kidney disease patients on hemodialysis from January 1st, 2017 to December 30th, 2022. Data were extracted from April 1st-May 20th, 2023, and each variable was coded and entered into Epi Data version 3.1 and then exported into STATA version 15 software for analysis. Kaplan-Meier and the log-rank test were done. Bivariable Cox-proportional regression was done, and a variable whose p-value was < 0.25 and fulfilled the proportional hazard assumption by using graphical and Shenfield residuals was entered into multivariable Cox-proportional regression. Finally, a variable whose p-value < 0.05 and adjusted hazard ratio with its CI were declared statistically significant predictors.
RESULT: In this study, the overall median survival time was 47 months (95% CI: 36.7, 56), with an incidence rate of death of 16.8 per 1000 people per month of observation (95% CI: 13.8-20.3). Age 64 and above (Adjusted Hazard Ration: 2.8; 95% CI: 1.67-4.98), catheter vascular access (Adjusted Hazard Ration: 3.47; 95% CI: 2.03-5.93), cardiovascular disease (Adjusted Hazard Ration: 1.88; 95% CI: 1.15-3.07), and blood group B (Adjusted Hazard Ration: 2.07; 95% CI: 1.17-3.69) were significant predictors of time to death among hemodialysis patients. CONCLUSION AND RECOMMENDATION: The median survival time was 47 months, with an interquartile range of 40. Cardiovascular disease, older adults, central venous catheters, and blood type B were significant predictors of time to death for hemodialysis patients. Therefore, in order to improve the survival of hemodialysis patients, health professionals and concerned bodies should give concern to and work on those predictors.
For intestinal perfusion, a tube assembly (outer diameter 7 mm) marked with a length scale is used. It consists of six tubes that are bonded together with tetrahydrofuran (Sigma Chemical Corp, St Louis, Missouri, USA). Three tubes are connected to a balloon which is used to occlude the intestinal lumen proximal to the site of infusion. Three tubes are radio-opaque to allow fluoroscopic location of the assembly; their distal end is immediately distal to the proximal occluding balloon(perfusion site) and positioned at 60 cm (duodenum), 90 cm (proximal jejunum) and 120 cm (distal jejunum) from the nose. After a 12 hour fast, the subjects swallow the tube assembly. The position of the assembly is confirmed by fluoroscopy. With the tube in the right position, the occluding balloon is inflated with 60 ml of air and perfusion of the distal intestinal segment is started. . The perfusion is performed using a continuous pump according to the following scheme:

100 ml/h during 30 minutes 110 ml/h during 60 minutes 123 ml/h during 60 minutes 133 ml/h during 30 minutes test period, which is followed by 120 minute absorption period. Each subject will be studied in 3 different sessions at 7-10 days distance randomly selected in order to study the effect on insulin sensitivity and secretion of a test meal delivery in different intestinal segments (i.e. at the duodenum, the proximal jejunum, and the distal jejunum). Blood samples for glucose, free fatty acids (FFA) insulin, C-peptide, glucagon, GLP-1, GIP, are drawn at -30 minutes and at 0, 15, 30, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 minutes during each of the test periods. The lipid-glucose-protein test meal is a mixture of ScandiShake(85 g of powder is mixed in 240-mL milk resulting in 69.5 g carbohydrates, 30.4 g fat, and 11.7 g protein).
The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
The present invention relates to the technical field of medical bioengineering, particularly to a thrombus targeting fusion protein mA5UKB with double functions of anticoagulation and thrombolysis. The protein is formed by the fusion of a mutant mAnxA5 of annexin 5 (A5) and urokinase chain B (UKB). The annexin (A5) has four homology structural domains, and the mAnxA5 only has a first structural domain and a second structural domain; the molecular weight of the mAnxA5 is one half of that of the annexin (A5), but the mAnxA5 retains the thrombus targeting function and the blood anticoagulation function of the annexin (A5); in addition, a valine-glycine-aspartic acid (V-G-D) sequence in the second structural domain is mutated to form an arginine-glycine-aspartic acid (R-G-D) sequence. Thus, the mAnxA5 has the function of blood anticoagulation. The mAnxA5 is fused with the UKB with a thrombolysis function, and the obtained fusion protein mA5UKB can act on a thrombus position in a targeting mode. Therefore, the efficiency of thrombolysis is increased, and adverse reaction, such as hemorrhage, etc., is reduced. The fusion protein of the present invention, which has the functions of anticoagulation and thrombolysis, can be prepared to obtain thrombolysis medicine.
Ciprofloxacin extended-release tablets was evaluated for the treatment of uncomplicated urinary tract infections (acute cystitis) in a randomized, double-blind, controlled clinical trial conducted in the US. This study compared ciprofloxacin extended-release tablets (500 mg once daily for three days) with ciprofloxacin immediate-release tablets (ciprofloxacin 250 mg BID for three days). Of the 905 patients enrolled, 452 were randomly assigned to the ciprofloxacin extended-release tablets treatment group and 453 were randomly assigned to the control group. The primary efficacy variable was bacteriologic eradication of the baseline organism(s) with no new infection or superinfection at test-of-cure (Day 4 -11 Post-therapy).

The bacteriologic eradication and clinical success rates were similar between ciprofloxacin extended-release tablets and the control group. The eradication and clinical success rates and their corresponding 95% confidence intervals for the differences between rates (ciprofloxacin extended-release tablets minus control group) are given in the following table:
This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
Patients with a diagnosis of Philadelphia chromosome- or BCR-ABL1-positive CML (as determined by cytogenetics, FISH, or PCR), prior evidence of a quantifiable BCR-ABL1 transcript by RT-PCR, and whom have been taking TKI for \> 36 months with a current status of complete molecular remission (CMR). TKI cessation begins within 7 days of study registration. Patients undergo BCR-ABL1 test every month in 24 months.
FIELD: oral care. ^ SUBSTANCE: tooth foaming fluorinated complex which contains the aqueous solution of the surface active component chosen from the group of non-ionic surfactants, zwitterionic surfactants, betain surfactants and their mixtures. Surface active components constitute from 0.1 to 3 mas.% per complex mass. Besides, the complex contains acidifier safe for oral administration. It consists of apple acid in quantity sufficient for the complex pH regulation from about 3 to 5. The complex while feeding makes the foam which disappears less than in 120 sec. The complex is stable in case of low temperature and is a clear solution that for the most part doesn't contain contaminants in case of holding for 12 hours at 4.4C. While splitting from the container to the cell of the tooth tray the complex makes fast-falling foam of low density that condenses in 1 minute after the splitting of the complex from the container and its contact with the patients' teeth. ^ EFFECT: invention strengthens teeth. ^ 16 cl, 3 tbl, 3 ex
BACKGROUND: Emicizumab is used as a subcutaneous prophylaxis for prevention of bleeding episodes in patients with haemophilia A (HA) with and without inhibitors. While low bleeding rates were observed in clinical trials, patients still experience breakthrough bleeds (BTBs) with emicizumab in the real-world. Current guidelines recommend use of recombinant activated factor VII (rFVIIa) for treatment of BTBs in patients with inhibitors. Due to thrombotic events observed in the HAVEN 1 study, activated prothrombin complex concentrate (aPCC) should be used with caution.
OBJECTIVES: The objective of this review is to identify and discuss real-world data on the frequency of BTBs and the safety of concomitant rFVIIa use in patients with inhibitors on emicizumab prophylaxis.
METHODS: A search of the following databases was conducted on 15 July 2022: BIOSIS Previews® , Current Contents Search® , Embase® , MEDLINE® . Search terms included 'real world', 'haemophilia A', and 'emicizumab'.
RESULTS AND CONCLUSIONS: Eleven relevant publications were identified (seven original research articles and four congress abstracts). The frequency of BTBs specifically for HA patients with inhibitors was described in three publications with 5%-56% patients on emicizumab reporting ≥1 bleeding episode. Treatment of these BTBs appeared to be managed according to relevant guidelines. Importantly, no thrombotic complications occurred during concomitant rFVIIa use. Due to the nature of real-world studies, direct comparison of the results between studies is limited. However, real-world data show that BTBs in inhibitor patients during emicizumab prophylaxis can be safely treated with rFVIIa.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to the development of complex homeopathic agents used for treatment of cough. The agent has Antimonium and Kalium tartaricum C3, Eucalyptus globulus C3, Drosera rotundifolium C3, Bryonia dioica C3, Ipecacuanha C6, Rumex crispus C3 being all components are taken at equal parts. The agent can be made as sugar granules. Treatment with this agent results to improvement of general state of patients: disappearance of lancinating pains in thorax, cough attack arresting, decreased safety and inflammatory symptoms in upper respiratory ways, normalized blood formula. EFFECT: enhanced effectiveness. 2 cl, 1 ex
Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
BACKGROUND: Female Genital Schistosomiasis (FGS) remains a critical and yet neglected topics in Neglected Tropical Diseases (NTDs), significantly affecting the health of women and girls worldwide. Health workers' knowledge of FGS is vital to the prevention and management of the disease. This study adopted an implementation research approach to identify and address the existing knowledge gap regarding FGS among healthcare workers in Ghana.
METHODS: This study was a 3-year (2020-2022) implementation research applying a pragmatic uncontrolled quasi-experimental study design. The study involved a baseline assessment, FGS training intervention for health workers and student nurses, distribution of FGS educational materials, and an endline assessment. A mixed-method approach was applied to data collection involving health workers from two schistosomiasis endemic districts and across the country. NVIVO 12 and STATA 14 were used for qualitative and quantitative data analysis, respectively.
RESULTS: Prior to the intervention, the level of awareness about FGS among health workers was less than 8%, and most participants only understood FGS as merely urogenital schistosomiasis in females. In response to this gap, an FGS education intervention in the form of training of health workers, student nurses alongside the distribution of FGS educational materials were carried out. The intervention enhanced health workers' awareness of FGS to more than 61%, encompassing an enhanced understanding of the disease's signs and symptoms to more than 60%, as well as its management strategies. However, access to praziquantel, the primary treatment, remained a significant challenge.
CONCLUSIONS: The FGS intervention effectively raised healthcare workers' awareness and knowledge. Expanding training and improving praziquantel access are essential for optimal FGS management. A multi-faceted approach involving individuals, communities, and the healthcare system is necessary for comprehensive FGS prevention and control.
FIELD: medicine, dermatovenerology. SUBSTANCE: invention proposes prescription of preparations on the first day after menses termination. Metronidazol is prescribed as an antitrichomoniasis preparation in the dose 500 mg, 3 times per 24 h, every day for one week. Orungal is prescribed as an antimycotic preparation in the dose 100 mg per 24 h, every day for one week and then in the dose 300 mg for 2 weeks. Method provides the enhancement of effectiveness of treatment, to reduce frequency of relapses of urogenital cadidiasis and to enhance indices of etiological recovery of trichomoniasis. Invention can be used in treatment of urogenital candidiasis on the background of trichomoniasis. EFFECT: enhanced effectiveness of treatment. 1 tbl
Hypoglycemic event prediction using machine learning is described. A CGM platform includes a machine learning model trained using historical time series glucose measurements of a user population. Once trained, the machine learning model predicts hypoglycemic events for users. When predicting hypoglycemic events, a time series of glucose measurements for a day time interval is received. The glucose measurements of this time series for the day time interval are provided by a CGM system worn by the user. The machine learning model predicts whether a hypoglycemic event will occur during a night time interval that is subsequent to the day time interval by processing the time series of glucose measurements using the trained machine learning model. The hypoglycemic event prediction is then output, such as via communication and/or display of a notification about the hypoglycemic event prediction.
The dose of sintilimab was 200mg per dose, intravenously, once every 3 weeks. Multimodal radiotherapy methods: ①SBRT: ≥1 independent lesion was selected, with a single dose of 8-10Gy and a total dose of 40-60Gy, divided into 5-6 times of radiotherapy. The final frequency and total dose of radiotherapy were determined by the radiologist.② Low-dose radiotherapy: ≥1 independent lesion was selected, and the single dose, the final frequency of radiotherapy and the total dose were determined by the radiologist.
PURPOSE:To obtain the subject safe composition, containing at least one selected from amino acids and derivatives thereof and proteins and hydrolyzates thereof and at least one selected from ellagic acid-based compounds and alkali metal salts thereof, capable of imparting moistness and glass to the skin and good in safety. CONSTITUTION:A skin drug composition for external use containing at least one selected from amino acids (e.g. alanine or cystine) and derivatives thereof (e.g. acylglutamic acid) and proteins (e.g. soybean protein) and hydrolyzates thereof and at least one selected from ellagic acid-based compounds (e.g. compounds obtained from natural products, such as eucalyptic wood) expressed by formula I (R1 to R4 are H, alkyl, alkoxy, polyoxyethylene residue or saccharide residue expressed by formula II; R5 is H, OH or alkoxy) and alkali metal salts thereof. The above-mentioned composition is excellent in action of imparting moistness and gloss to the skin, safety and stability.
Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.